Cargando…
Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock
BACKGROUND: Sepsis is a leading cause of death despite appropriate management. There is increasing evidence that microcirculatory alterations might persist independently from macrohemodynamic improvement and are related to clinical evolution. Future efforts need to be directed towards microperfusion...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847092/ https://www.ncbi.nlm.nih.gov/pubmed/24007807 http://dx.doi.org/10.1186/2110-5820-3-30 |
_version_ | 1782293537827586048 |
---|---|
author | Masip, Jordi Mesquida, Jaume Luengo, Cecilia Gili, Gisela Gomà, Gemma Ferrer, Ricard Teboul, Jean Louis Payen, Didier Artigas, Antonio |
author_facet | Masip, Jordi Mesquida, Jaume Luengo, Cecilia Gili, Gisela Gomà, Gemma Ferrer, Ricard Teboul, Jean Louis Payen, Didier Artigas, Antonio |
author_sort | Masip, Jordi |
collection | PubMed |
description | BACKGROUND: Sepsis is a leading cause of death despite appropriate management. There is increasing evidence that microcirculatory alterations might persist independently from macrohemodynamic improvement and are related to clinical evolution. Future efforts need to be directed towards microperfusion monitoring and treatment. This study explored the utility of thenar muscle oxygen saturation (StO(2)) and its changes during a transient vascular occlusion test (VOT) to measure the microcirculatory response to drotrecogin alfa (activated) (DrotAA) in septic patients. METHODS: A prospective, observational study was performed in three general intensive care units at three university hospitals. We studied 58 patients with recent onset of severe sepsis or septic shock and at least two organ dysfunctions. Thirty-two patients were treated with DrotAA and 26 were not treated because of formal contraindication. StO(2) was monitored using near-infrared spectroscopy (NIRS), and VOT was performed to obtain deoxygenation (DeOx) and reoxygenation (ReOx) slopes. Measurements were obtained before DrotAA was started and were repeated daily for a 96-hour period. RESULTS: Patients’ characteristics, outcome, severity, and baseline values of StO(2), DeOx, and ReOx did not differ between groups. Treated patients significantly improved DeOx and ReOx values over time, whereas control patients did not. In treated patients, ReOx improvements were correlated to norepinephrine dose reductions. Early clinical response (SOFA improvement after 48 hours of treatment) was not associated to changes in VOT-derived slopes. In the treated group, the relative improvement of DeOx within 48 hours was able to predict mortality (AUC 0.91, p < 0.01). CONCLUSIONS: In patients with severe sepsis or septic shock, DrotAA infusion was associated with improvement in regional tissue oxygenation. The degree of DeOx amelioration after 2 days in treated patients predicted mortality with high sensitivity and specificity. Thus, StO(2) derived variables might be useful to evaluate the microcirculatory response to treatment of septic shock. |
format | Online Article Text |
id | pubmed-3847092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Springer |
record_format | MEDLINE/PubMed |
spelling | pubmed-38470922013-12-06 Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock Masip, Jordi Mesquida, Jaume Luengo, Cecilia Gili, Gisela Gomà, Gemma Ferrer, Ricard Teboul, Jean Louis Payen, Didier Artigas, Antonio Ann Intensive Care Research BACKGROUND: Sepsis is a leading cause of death despite appropriate management. There is increasing evidence that microcirculatory alterations might persist independently from macrohemodynamic improvement and are related to clinical evolution. Future efforts need to be directed towards microperfusion monitoring and treatment. This study explored the utility of thenar muscle oxygen saturation (StO(2)) and its changes during a transient vascular occlusion test (VOT) to measure the microcirculatory response to drotrecogin alfa (activated) (DrotAA) in septic patients. METHODS: A prospective, observational study was performed in three general intensive care units at three university hospitals. We studied 58 patients with recent onset of severe sepsis or septic shock and at least two organ dysfunctions. Thirty-two patients were treated with DrotAA and 26 were not treated because of formal contraindication. StO(2) was monitored using near-infrared spectroscopy (NIRS), and VOT was performed to obtain deoxygenation (DeOx) and reoxygenation (ReOx) slopes. Measurements were obtained before DrotAA was started and were repeated daily for a 96-hour period. RESULTS: Patients’ characteristics, outcome, severity, and baseline values of StO(2), DeOx, and ReOx did not differ between groups. Treated patients significantly improved DeOx and ReOx values over time, whereas control patients did not. In treated patients, ReOx improvements were correlated to norepinephrine dose reductions. Early clinical response (SOFA improvement after 48 hours of treatment) was not associated to changes in VOT-derived slopes. In the treated group, the relative improvement of DeOx within 48 hours was able to predict mortality (AUC 0.91, p < 0.01). CONCLUSIONS: In patients with severe sepsis or septic shock, DrotAA infusion was associated with improvement in regional tissue oxygenation. The degree of DeOx amelioration after 2 days in treated patients predicted mortality with high sensitivity and specificity. Thus, StO(2) derived variables might be useful to evaluate the microcirculatory response to treatment of septic shock. Springer 2013-09-04 /pmc/articles/PMC3847092/ /pubmed/24007807 http://dx.doi.org/10.1186/2110-5820-3-30 Text en Copyright © 2013 Masip et al.; licensee Springer. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Masip, Jordi Mesquida, Jaume Luengo, Cecilia Gili, Gisela Gomà, Gemma Ferrer, Ricard Teboul, Jean Louis Payen, Didier Artigas, Antonio Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock |
title | Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock |
title_full | Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock |
title_fullStr | Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock |
title_full_unstemmed | Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock |
title_short | Near-infrared spectroscopy StO(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock |
title_sort | near-infrared spectroscopy sto(2) monitoring to assess the therapeutic effect of drotrecogin alfa (activated) on microcirculation in patients with severe sepsis or septic shock |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3847092/ https://www.ncbi.nlm.nih.gov/pubmed/24007807 http://dx.doi.org/10.1186/2110-5820-3-30 |
work_keys_str_mv | AT masipjordi nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock AT mesquidajaume nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock AT luengocecilia nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock AT giligisela nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock AT gomagemma nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock AT ferrerricard nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock AT tebouljeanlouis nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock AT payendidier nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock AT artigasantonio nearinfraredspectroscopysto2monitoringtoassessthetherapeuticeffectofdrotrecoginalfaactivatedonmicrocirculationinpatientswithseveresepsisorsepticshock |